What is the definition of Systemic Lupus Erythematosus (SLE)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Definition of Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a complex multisystemic autoimmune disease characterized by loss of immune tolerance, production of autoantibodies against nuclear antigens, immune complex deposition, and chronic inflammation affecting multiple organ systems. 1

Core Pathophysiologic Features

The disease fundamentally represents a failure of immunological tolerance, leading to pathogenic autoantibody production that is present in virtually all patients. 1, 2 This process involves:

  • Autoantibody formation against nuclear components, particularly anti-double-stranded DNA (anti-dsDNA) and anti-Smith (anti-Sm) antibodies 1, 3
  • Immune complex deposition in tissues with subsequent complement activation 1, 2
  • Recruitment of inflammatory cells and resulting tissue damage across multiple organ systems 1

Clinical Characteristics

SLE presents as a multisystem disease that can affect virtually any organ, though it may occasionally be limited to one or few organs at presentation. 4 The disease is diagnosed on clinical grounds in the presence of characteristic serological abnormalities. 4

Key affected systems include:

  • Mucocutaneous manifestations (characteristic rashes, photosensitivity, mouth ulcers, alopecia) 1, 3
  • Musculoskeletal involvement (arthritis, joint pain, myalgia) 1, 3
  • Renal disease (proteinuria, lupus nephritis in approximately 40% of patients) 1, 5
  • Hematologic abnormalities (cytopenias, thrombocytopenia, anemia) 1
  • Neuropsychiatric manifestations (seizures, psychosis) 4, 1
  • Cardiovascular and pulmonary complications 1

Epidemiologic Profile

The disease predominantly affects women during their childbearing years, with approximately 90% of patients being female. 1, 5 Approximately half a million people in Europe and a quarter of a million in the USA have SLE. 4

Populations at higher risk include:

  • Latin American, North American Mestizo, African descendants, and Native Americans, who develop lupus earlier with more severe disease, higher activity, greater organ damage accumulation, and higher mortality rates 1

Disease Course

SLE runs a highly variable clinical course characterized by remissions and flares. 4 The disease can take a chronic or relapsing-remitting course, with presentations ranging from mild rashes and arthritis to debilitating fever, fatigue, and severe life-threatening organ involvement. 6

Diagnostic Framework

The 2019 EULAR/ACR classification criteria are 96.1% sensitive and 93.4% specific for SLE, requiring both clinical manifestations and immunologic abnormalities. 1, 5 These criteria systematically evaluate:

Clinical features (weighted within each domain):

  • Fever 1, 3
  • Cytopenia 1, 3
  • Characteristic rash 1, 3
  • Arthritis 1, 3
  • Serositis 1
  • Proteinuria 1, 3

Immunologic markers:

  • Anti-dsDNA antibodies 1, 3
  • Anti-Sm antibodies 1, 3
  • Hypocomplementemia 1, 3
  • Antiphospholipid antibodies 1, 3
  • Anti-Ro/SSA and anti-La/SSB antibodies 1

Etiologic Factors

The development of SLE involves an interaction between genetic susceptibilities and environmental triggers. 1 Genetic factors include MHC polymorphisms, while environmental triggers particularly include viral infections that can precipitate disease onset. 1, 2

References

Guideline

Systemic Lupus Erythematosus: Clinical Overview and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Imunocomplexos e Doenças Relacionadas

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Systemic lupus erythematosus.

Lancet (London, England), 2024

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Systemic lupus erythematosus: an overview.

Social work in health care, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.